AI assistant
LABCORP HOLDINGS INC. — Director's Dealing 2019
Apr 5, 2019
30237_dirs_2019-04-05_7d911427-c76b-4883-a862-4926d519765a.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: LABORATORY CORP OF AMERICA HOLDINGS (LH)
CIK: 0000920148
Period of Report: 2019-04-03
Reporting Person: Ratliff John D (CEO, Covance Drug Development)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2019-04-03 | Common Stock | M | 2424 | — | Acquired | 18025 | Direct |
| 2019-04-03 | Common Stock | F | 1084 | $156.68 | Disposed | 16941 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2019-04-03 | Restricted Stock Unit | $ | M | 2424 | Disposed | Common Stock (2424) | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 40 | Indirect |
| Common Stock | 80 | Indirect |
Footnotes
F1: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock.
F2: Stock withholding to satisfy tax withholding obligations.
F3: The Restricted Stock Units vest in three installments as follows: 20% of the Restricted Stock Units vested on April 3, 2019; 30% of the Restricted Stock Units will vest on April 3, 2020; and 50% of the Restricted Stock Units will vest on April 3, 2021.
F4: This number reflects the aggregate number of Restricted Stock Units held by the reporting person.